Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, Italy

•MOGAD incidence and prevalence are still unclear.•We report incidence and prevalence of MOGAD in Verona province, Italy.•Prevalence-incidence lower than MS, higher than NMOSD with AQP4-IgG in Caucasians.•More frequent disease onset in autumn-winter period. Myelin oligodendrocyte glycoprotein (MOG)...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Multiple sclerosis and related disorders Ročník 63; s. 103884
Hlavní autoři: Orlandi, Riccardo, Mariotto, Sara, Gajofatto, Alberto
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier B.V 01.07.2022
Témata:
Demyelinating diseases
MOGAD
Neuroepidemiology
Neuroimmunology
Neurology
MOGAD
Demyelinating diseases
Neuroimmunology
Neuroepidemiology
ISSN:2211-0348, 2211-0356, 2211-0356
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:•MOGAD incidence and prevalence are still unclear.•We report incidence and prevalence of MOGAD in Verona province, Italy.•Prevalence-incidence lower than MS, higher than NMOSD with AQP4-IgG in Caucasians.•More frequent disease onset in autumn-winter period. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a demyelinating disorder of the central nervous system whose epidemiological features are still unclear. We report current prevalence and incidence rates of MOGAD in the population of Verona province, Italy, and the seasonal distribution of disease onset. MOGAD patients residing in Verona province were included through the consultation of a database from our Neuropathology Laboratory. Provincial prevalence was determined on 2021/1/1 (resident population: 922,291 people) and incidence rates between 2016/1/1 and 2021/1/1 were calculated from all cases, divided by the total number of person-years at risk. We also examined the distribution of attacks by month and season. We included 23 prevalent MOGAD cases (13 females), with a median age at onset of 36 years (range 5–69). Prevalence rate was 2.5/100,000 (95% CI 1.7–3.7). 22 incident cases were collected, with an incidence rate of 4.8/million person-years (95% CI 3.1–7.2). Among the 23 prevalent patients, disease onset was more frequent in December (4 cases), February, May, and September (3 cases/month), with a global autumn-winter predominance (September-February) of 15 cases (65%), irrespective of the clinical manifestation. This is the first study on an Italian population to report MOGAD prevalence and incidence rates; they are higher than the estimates for aquaporin-4-seropositive neuromyelitis optica spectrum disorder in the Caucasian population, but far lower than Multiple Sclerosis. An autumn-winter predominance of disease onset is suggested, and it could be related to environmental factors that should be ascertained, although validation in larger cohorts is mandatory.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2211-0348
2211-0356
2211-0356
DOI:10.1016/j.msard.2022.103884